within Pharmacolibrary.Drugs.ATC.D;

model D11AH02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D11AH02</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Pimecrolimus is a topical calcineurin inhibitor used primarily in the treatment of atopic dermatitis (eczema). It acts as an immunomodulating agent that inhibits T-cell activation by blocking the production and release of pro-inflammatory cytokines and mediators from T-cells. Currently, it is approved for use in mild to moderate atopic dermatitis and is available in topical formulations.</p><h4>Pharmacokinetics</h4><p>Adults and children with atopic dermatitis treated topically with 1% pimecrolimus cream.</p><h4>References</h4><ol><li><p>Lo, A, et al., &amp; Feldman, SR (2024). Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients. <i>Expert opinion on drug metabolism &amp; toxicology</i> 20(4) 235–248. DOI:<a href=\"https://doi.org/10.1080/17425255.2024.2337749\">10.1080/17425255.2024.2337749</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38553411/\">https://pubmed.ncbi.nlm.nih.gov/38553411</a></p></li><li><p>Gupta, AK, &amp; Chow, M (2003). Pimecrolimus: a review. <i>Journal of the European Academy of Dermatology and Venereology : JEADV</i> 17(5) 493–503. DOI:<a href=\"https://doi.org/10.1046/j.1468-3083.2003.00692.x\">10.1046/j.1468-3083.2003.00692.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12941081/\">https://pubmed.ncbi.nlm.nih.gov/12941081</a></p></li><li><p>Prucha, H, et al., &amp; Traidl-Hoffmann, C (2013). Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema. <i>Expert opinion on drug metabolism &amp; toxicology</i> 9(11) 1507–1516. DOI:<a href=\"https://doi.org/10.1517/17425255.2013.819343\">10.1517/17425255.2013.819343</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23876065/\">https://pubmed.ncbi.nlm.nih.gov/23876065</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D11AH02;
